High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Wei XuJian-Yong Li

Abstract

To evaluate the clinical efficacy and safety of high-dose methylprednisolone (HDMP) in patients with fludarabine-refractory chronic lymphocytic leukaemia (CLL). Twelve patients who were refractory to fludarabine-based treatment were treated with 2-6 cycles of HDMP (1g/m(2) for 5days). Ten patients (83.3%) responded to treatment and three (25.0%) achieved a complete remission (CR). Two (16.7%) of which had no evidence of minimal residual disease (MRD) after treatment. Patients with leukaemia cells that have high expression of ZAP-70 or CD38, unmutated immunoglobulin heavy chain variable region (IGHV), mutated p53 or adverse cytogenetic features achieved response to treatment at rates that appeared similar to those achieved by patients who did not have such disease characteristics. With a median follow-up of 13 (4-30) months, the median overall survival (OS) and the progression-free survival (PFS) have not been achieved. Treatment with HDMP was well tolerated, notably in the patients having poor myeloid reserve and pretreated cytopaenias. HDMP is an effective non-myelotoxic regimen for the treatment of patients with fludarabine-refractory CLL.

References

Oct 11, 2003·Annals of Hematology·Patrick D ThorntonDaniel Catovsky
Jan 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francesc BoschEmili Montserrat

❮ Previous
Next ❯

Citations

May 24, 2012·Expert Opinion on Investigational Drugs·Lukáš Smolej
Jul 22, 2014·British Journal of Haematology·Polina ShindiapinaAlexey V Danilov
Jun 1, 2011·Therapeutic Advances in Hematology·Saman Hewamana, Claire Dearden

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis